Long-term safety and efficacy of plixorafenib in patients with BRAF-altered CNS neoplasms from the Phase 1/2a PLX120-03 study

Press Release Nov 05 2026 FORE Biotherapeutics to Participate in Upcoming Investor Conferences Read more

Press Release Nov 04 2026 FORE Biotherapeutics to Present New Clinical and Preclinical Plixorafenib Data at Upcoming Oncology Medical Meetings Read more

Press Release Sep 01 2026 FORE Biotherapeutics to Participate in Upcoming Investor Conferences Read more